Windgap, successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital. This equity round of investment expanded beyond an initial target of approximately $32 million due to strong investor interest. This equity financing is also supported by existing investors, including Shepherd Kaplan Krochuk (SKK) and Molex Ventures (a Koch Industries company), along with new investors including Cobro Ventures, and others.
Windgap is working to commercialize its ANDI® wet/dry autoinjector platform, which would introduce a more compact, stable, temperature-resilient option for many medications currently in the marketplace.
|